Currently Viewing:
AMCP 2017
Analyzing the Near-Term Pipeline for Specialty Drugs
March 28, 2017
Dr Aimee Tharaldson Highlights Two Key Drugs for 2017
March 28, 2017
Effectively Moving Toward Value-Based Care
March 28, 2017
Susan A. Cantrell on the Evolution of Value Frameworks
March 28, 2017
Dr Liz Zhou Explains Basal Insulin Switching Study on Toujeo
March 28, 2017
Dr Richard Willke on Using Real-World Data to Inform Value-Based Contracts
March 29, 2017
The Unsustainably Big Business of Healthcare
March 29, 2017
Dr Matthew Pickering: How Quality Measures Are Created and Implemented
March 29, 2017
Addressing the Affordability Issue of Novel Treatments
March 29, 2017
Dr Clifford Goodman Outlines Takeaways From a Health Economic Case Study on Repatha
March 30, 2017
Dr Doug Hillblom on the State of e-Prescribing and Remaining Barriers
March 30, 2017
Cardiovascular Outcome Trials: How Misinterpretation of Statistics Can Affect Clinical Practice
March 30, 2017
Repatha Offers Additional LDL-C Reduction in a Convenient Dosage Form
March 30, 2017
ACA Repeal and Other Healthcare Issues on the Trump Administration's Agenda
April 03, 2017
The Latest in the Move to Value-Based Reimbursement and Remaining Challenges
April 04, 2017
Susan Cantrell: Uncertainty Is Affecting Everyone in Healthcare
April 11, 2017
Dr Aimee Tharaldson Discusses 2 New Treatments for Tardive Dyskinesia
April 12, 2017
Dr Gail Bridges Explains the High Real-World Cure Rate for HCV
April 17, 2017
Dr Richard Willke Previews ISPOR 2017 in Boston
April 18, 2017
Dr Matthew Pickering Discusses Development, Implementation of Quality Measures
April 20, 2017
Currently Reading
Dr Doug Hillblom Expects Evolution of e-Prescribing to Continue
April 22, 2017
Susan A. Cantrell Outlines Concerns and Opportunities for Managed Care
May 01, 2017
The Importance of Ethical Committees in the Evolving Healthcare Environment
May 11, 2017
Dr Lou Garrison on the Discussions Surrounding Outcomes-Based Arrangements
May 17, 2017

Dr Doug Hillblom Expects Evolution of e-Prescribing to Continue

As the use of e-prescribing expands, it will begin to encompass more than just writing an initial prescription to include many interactions between healthcare providers, according to Doug Hillblom, PharmD, president at Arena Healthcare, LLC.


As the use of e-prescribing expands, it will begin to encompass more than just writing an initial prescription to include many interactions between healthcare providers, according to Doug Hillblom, PharmD, president at Arena Healthcare, LLC.

Transcript (slightly modified)

What future changes in e-prescribing do you expect to see?

I expect to see more adoption. I expect to see more uses. I think that you’re going to be seeing potentially… Well, a change that we did see was the electronic prescribing of controlled substances. It started off initially that that was not allowed, now it is allowed and it’s become really a standard, so I think you’re going to see continued evolution. As both physicians, pharmacies, and the healthcare system change, you’re going to see continued evolution.

You’re going to see more and more work done: can we add things into the process? I think you’re going to see, when we talk about prescribing in general, we think about refills, we think about fill status, we think about prior authorization, those are all components of what people in the standards organization think about e-prescribing. E-prescribing is not just initiating a prescription. It’s a whole host of data interchange or transactions or interactions between physicians, pharmacies, payers, et cetera.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!